As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and other cardiovascular events in a late-stage clinical trial.

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...

Danish pharmaceutical company Novo Nordisk (NVO -0.47%) is pioneering a new wave of medical treatment for diabetes and obesity care. The company develops a long line of blockbuste ...

On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard ...

A new pill called Naltrexone, known as 'Ozempic for drinking,' helps reduce alcohol cravings by blocking the euphoric effects ...

GLP-1 medications, such as Ozempic, may interact with other drugs, causing very low blood sugar levels or disrupting the ...

Oral contraceptives, certain pregnancy complications, and early menopause can all increase the risk of a first stroke. But ...

including topical and oral antibiotics, hormonal treatments, and lifestyle changes. Semaglutide medications such as Ozempic and Wegovy can help with weight management and blood sugar regulation ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist, Rybelsus, which is currently approved for type 2 ...